DDRE-10. IMMUNE PROFILES ASSOCIATE WITH OUTCOMES IN HLA-A*02:01(+), H3.3K27M(+) PATIENTS WITH DIFFUSE MIDLINE GLIOMAS TREATED WITH H3.3K27M PEPTIDE VACCINE COMBINED WITH POLY-ICLC: A PNOC REPORT

BACKGROUND: Patients with diffuse midline gliomas (DMG), including diffuse intrinsic pontine glioma (DIPG), have dismal outcomes. We previously described the H3.3K27M mutation as a shared neoantigen in HLA-A*02.01(+) H3.3K27M(+) DMGs. Within the Pacific Pediatric Neuro-Oncology Consortium, we assess...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Mueller, Sabine, Taitt, Jared M, Villanueva-Meyer, Javier, Bonner, Erin R, Nejo, Takahide, Lulla, Rishi R, Goldman, Stewart, Banerjee, Anurhada, Chi, Susan, Whipple, Nicholas S, Crawford, John R, Gauvain, Karen, Nazemi, Kellie, Watchmaker, Payal, Almeida, Neil D, Okada, Kaori, Salazar, Andres, Gilbert, Ryan, Nazarian, Javad, Molinaro, Annette, Butterfield, Lisa H, Prados, Michael, Okada, Hideho
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2020
Pynciau:
Drug Discovery, Drug Resistance
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651114/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.255
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg